CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on genomics, today announced that it is scheduled to present at LD MICRO’s 5 th Annual Conference on Thursday, December 6, 2013, at 10 a.m. Pacific Standard Time. The December 5-6 conference is to be held at the Luxe Sunset Bel Air Hotel at 11461 Sunset Boulevard in Los Angeles, CA.
CollabRx Chairman and Co-CEO Thomas R. Mika will be presenting to investors and available for one-on-one meetings during the conference.
CollabRx uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on molecular medicine with specific insights from the nation’s top clinical experts. The company combines proprietary content and technology to provide clinically relevant and dynamically updated knowledge on clinical trials, drugs, biologics and other information relevant for cancer treatment planning. This knowledge is supported by CollabRx’s large and growing network of over 50 leading clinical practitioners in the United States. While CollabRx and its advisors do not provide specific treatment recommendations, this clinically relevant knowledge is a key part of the “context engine” for informing healthcare decision-making.
About LD MICROLD MICRO is a by-invitation-only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks, as well as comprehensive reports on select companies throughout the year. The firm also hosts the LD MICRO Micro-Cap Growth Conference for institutional investors in December of each year. LD MICRO concentrates on finding, researching and investing in companies that are overlooked by most institutional investors. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com. About CollabRx CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV